Bronkris indications
Bronkris hydrochloride SYRUP indicated for cough associated with wheeziness (bronchospasm) and tenacious phlegm (sputum).
Uses of Bronkris in details
Bronkris is used to treat breathing difficulties caused by excessive mucus secretions in the air passages associated with respiratory tract infections.
Bronkris description
Each tablet also contains lactose, maize or potato starch, gelatine and magnesium stearate as excipients.
The oral/inhalation solution also contains tartaric acid and methyl parahydroxybenzoate as excipients.
The syrup also contains tartaric acid, benzoic acid, sodium carboxymethylcellulose, glycerol, sorbitol solution, pharma flavor and ethanol as excipients.
Each capsule also contains lactose, cornstarch and magnesium stearate as excipients.
Bronkris is N-cyclohexyl-N-methyl-(2-amino-3,5-dibromobenzyl)amine hydrochloride.
Bronkris dosage
Unless otherwise prescribed, the following doses are recommended:
Tablet: Adults and Children >12 years: 8 mg (1 tab) thrice daily; 6-12 years: 4 mg (½ tab) thrice daily; 2-6 years: 4 mg (½ tab) twice daily.
Oral Solution:
Adults and Children >12 years: 4 mL thrice daily; 6-12 years: 2 mL thrice daily; 2-6 years: 20 drops thrice daily; <2 years: 10 drops thrice daily.Inhalation Solution (with aerosol apparatus): It is generally recommended to warm inhalation solution to body temperature before inhalation. Patients with bronchial asthma may be advised to commencing inhalation after they have taken their regular bronchospasmolytic therapy.
Adults: 4 mL. Children >12 years: 2 mL; 6-12 years: 1 mL; 2-6 years: 10 drops; <2 years: 5 drops. All doses to be taken twice daily.
The solution may be diluted 1:1 in physiological saline solution. In order to avoid precipitation, the solution should be inhaled immediately after mixing. The combined administration of inhalation and oral application intensifies the effect, and is especially suited for the commencement of treatment in cases where the full effect is to be reached quickly.
Syrup: Adults and Children >12 years: 5 ml (1 tsp) thrice daily.
At commencement of treatment, it may be necessary to increase the total daily dose up to 48 mg in adults.
The syrup is sugar-free and therefore suitable for diabetics and small children.
Ampoule: Severe cases, before and after surgical intervention: 1 amp SC, IM or IV (duration of injection: 2-3 min) 2-3 times daily.
Capsule: Adults: 1 cap 3 times daily.
It is recommended for the initial phase of treatment usually lasting not more than a week.
Patients being treated with Bronkris should be notified of an expected increase in the flow of secretions.
Bronkris interactions
A reduction in dose of cardiac glycosides (e.g. digitalis) and quinidine might become necessary in patients suffering from congestive cardiac failure because of the positive inotropic effect of orciprenaline sulphate.
Bronkris hydrochloride SYRUP should not be administered concomitantly with beta-blocking agents, due to orciprenaline’s reversal of anti-hypertensive action.
The concomitant use of other sympathomimetic agents should be carefully controlled to avoid potentiation of effects.
Bronkris side effects
Bronkris’s pharmacological action may lead to gastric irritation. A transient rise in serum aminotransferase values have been reported due to Bronkris.
Orciprenaline sulphate, as a sympathomimetic agent, may precipitate a wide range of adverse effects. Side-effects include fear; anxiety, restlessness, tremor, insomnia, confusion, irritability, weakness and psychotic states. Appetite may be reduced and nausea and vomiting may occur. A rise in blood pressure which may produce cerebral haemorrhage and pulmonary oedema, tachycardia and cardiac arrhythmias, anginal pain, palpitations, and cardiac arrest. Hypotension with dizziness and fainting and flushing may occur. Other effects that may occur include difficulty in micturition and urinary retention; dyspnoea; weakness; headache; disturbances of glucose metabolism; sweating and hypersalivation. Muscle cramps or twitching or unpleasant taste may occur.
Bronkris contraindications
Bronkris hydrochloride SYRUP is contra-indicated in patients with known hypersensitivity to sympathomimetic amines or any of the other ingredients; hypertrophic obstructive cardiomyopathy; and tachyarrhythmia.
Sympathomimetics, such as orciprenaline sulphate, may interact with monoamine oxidase inhibitors (MAOI), and therefore Bronkris hydrochloride SYRUP should not be given to patients receiving such treatment or within 14 days of MAOI treatment termination.
Safety in pregnancy and lactation has not been established.
Active ingredient matches for Bronkris:
Bromhexine in Indonesia.
Bromhexine HCl in Indonesia.
Unit description / dosage (Manufacturer) | Price, USD |
Bronkris 8 mg x 10 x 10's | $ 0.88 |
Bronkris 4 mg/5 mL x 60 mL x 1's | $ 1.69 |
List of Bronkris substitutes (brand and generic names): | |
Bronkosyrup-EX (India) | |
BRONKOSYRUP-EX syr 100ml (GSK) | $ 0.15 |
Bronmucon (Thailand) | |
Bronmucon 8 mg x 500's | |
Bronmucon 4 mg/5 mL x 60 mL | |
Bronq-T | |
Bronq-T 100 ml Syrup (Dutech Remedies (I) Pvt. Ltd.) | $ 0.02 |
Bronquisedan Elixir (Argentina) | |
Bronquisedan Paediatrico (Argentina) | |
Bronquisol (Colombia) | |
Bronsim (India) | |
Bronsim Terbutaline sulphate 1.25 mg, Bromhexine hydrochloride 2 mg, Guaifenesin 50 mg, Menthol 1mg/5 mL. SYR / 100ml (Siomond Pharmaceuticals Pvt Ltd) | $ 0.60 |
100ml (Siomond Pharmaceuticals Pvt Ltd) | $ 0.60 |
Bronsim 100 ml Syrup (Siomond Pharmaceuticals Pvt Ltd) | $ 0.03 |
BRONSIM syr 100ml (Siomond Pharmaceuticals Pvt Ltd) | $ 0.60 |
Brontol (Colombia) | |
Brontuss M (Colombia) | |
Brontuss M Pediatrico (Colombia) | |
Broomhexine (Netherlands) | |
Liquid; Oral; Bromhexine Hydrochloride 4 mg / 5 ml | |
Liquid; Oral; Bromhexine Hydrochloride 8 mg / 5 ml | |
Tablet; Oral; Bromhexine Hydrochloride 8 mg | |
Broomhexine 2% (Netherlands) | |
Broomhexine HCI SAM (Netherlands) | |
Broomhexine HCI Sameko (Netherlands) | |
Broomhexine HCl (Netherlands) | |
Broomhexine HCl Apotex (Netherlands) | |
Broomhexine HCL Basic (Netherlands) | |
Broomhexine HCl CF (Netherlands) | |
Broomhexine HCl DA (Netherlands) | |
Broomhexine HCl drank (Netherlands) | |
Broomhexine HCl HTP (Netherlands) | |
Broomhexine HCl Katwijk (Netherlands) | |
Broomhexine HCl Kring (Netherlands) | |
Broomhexine HCL MAE (Netherlands) | |
Broomhexine HCl Mdq (Netherlands) | |
Broomhexine HCl PCH (Netherlands) | |
Broomhexine HCl ratiopharm (Netherlands) | |
Broomhexine HCl RXT (Netherlands) | |
Broomhexine HCl SAM (Netherlands) | |
Broomhexine HCl Samenwerkende Apothekers (Netherlands) | |
Broomhexine HCl Sandoz (Netherlands) | |
Broomhexine HCl SDG (Netherlands) | |
Broomhexine HCl Teva (Netherlands) | |
Broomhexine HCl triangle pharma (Netherlands) | |
Broomhexine Hydrochloride (Netherlands) | |
Broomhexine Hydrochloride 4mg (Netherlands) | |
See 1940 substitutes for Bronkris |
References
- PubChem. "bromhexine". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "Bromhexine". http://www.drugbank.ca/drugs/DB09019 (accessed September 17, 2018).
- MeSH. "Expectorants". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Bronkris are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Bronkris. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology